Unveiling Sequential Bio’s New London Lab testing HQ

18th October 2022 - In an effort to keeping the entire testing process in-house, allowing for rigorous quality control, and meeting the demand of our European clients - today we announce the opening of our testing lab in London.

​

Sequential is proud to announce that it will open a European HQ, and testing lab site in White City, London. One key quality that makes Sequential stand out from its competitors is keeping the testing protocols and quantitative analysis in-house. This gives them the ability to ensure the processing, and targeting of microbiome markers for their clients is extremely high quality.

​

“Innovative R&D, and rigorous quality control on our lab testing and processes have always been front of mind at Sequential. By opening a lab in London, we’re responding to the demand from customers - whilst retaining control over our quality in testing.” - Dr Oliver Worsley, CEO/Co-Founder.

​

Adding to their testing labs in Singapore, and New York, in which they serve Singapore, Thailand, Australia, and the US markets. This enables faster turnaround time for European clients, as the demand for non-invasive molecular analysis of the skin reaches new heights in Europe.

​

Between 2018 - 2022, there have been over 34 microbiome deals (licensing and investments) made. With an average contract value of $257M, this has created over $2.3B of value in the gut and skin microbiome space. Europe is a significant player in the global microbiome field, expected to grow at a CAGR of 24.25% (between 2022-2028).

​

About Sequential

​

Sequential is part of the Sequential Skin group – with a US lab in New York City, alongside a lab in London and a lab in Singapore. Sequential Bio team has over 20 years of combined expertise in genetics, epigenetics, and microbiome research. It was recognised recently as the “Most Significant” Testing Method in the Industry.

​

Sequential has validated its AI-driven testing platform with over 30 companies, analyzing over 12,000 skin microbiome samples. They specialise in skin, scalp and vulva/vaginal microbiome samples.

​

They are supported by Enterprise SG, A*STAR, Genome Institute of Singapore, IndieBio New York, SOSV, Metaplanet Holdings, Scrum Ventures, Genedant VC, Ben Holmes (ex. General Partner at Index Ventures), Innovate UK, and are a resident company of Johnson & Johnson Innovation – JLABS.

​

​